In Warsaw, under the presidency of Poland in the EU Council, the 120th meeting of the Heads of Medicines Agencies (HMA) was held, in which Ukraine participated as an invited party. The event was aimed at bringing together key regulatory bodies of the EU to jointly discuss challenges in the field of health care and strengthen the resilience of the regulatory system. About this informs press office of the Ministry of Health.
The organizer was the Office of Registration of Medicinal Products, Medical Products and Biocidal Products of Poland. The meeting was chaired by the President of the Management, Grzegorz Cessak. Katarzyna Katzperczyk, Deputy Minister of Health of Poland, also took an active part.
The Ukrainian delegation was represented by specialists of the State Expert Center of the Ministry of Health of Ukraine and the State Service of Ukraine for Medicinal Products and Drug Control. The delegation was headed by Maryna Slobodnichenko, Deputy Minister of Health for European Integration.
“Ukraine’s participation in this meeting is a unique opportunity to get acquainted with new trends, exchange experience and adopt the best practices of the EU’s regulatory policy. At the same time, we are ready to share our own experience of ensuring the stability of the health care system and regulatory mechanisms in conditions of full-scale war. After all, the challenges we face every day are becoming more and more relevant for the whole of Europe.” Maryna Slobodnichenko explained.
The participants of the meeting discussed the key steps necessary for Ukraine to advance in the direction of European integration, in particular regarding the creation of an effective and strict regulatory system in the field of medicines. Each participating country shared its experience and expressed support for the Ukrainian pharmaceutical sector.
It was also emphasized the importance for Ukrainian manufacturers to understand the mechanisms of registration procedures in the EU – centralized, decentralized and mutual recognition. Separately discussed the issues of transitional periods that may be foreseen during the accession to the EU, in particular in the context of updating registration dossiers for medicinal products for national manufacturers.
